Skip to main content
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. — Investor Relations & Filings

Ticker · CMMB ISIN · US16385C1045 US Manufacturing
Open in API
Filings indexed 332 across all filing types
Latest filing 2012-11-05 Capital/Financing Update
Country US United States of America
Listing US CMMB

About Chemomab Therapeutics Ltd.

https://www.chemomab.com/

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's scientific platform is based on the discovery of the soluble protein CCL24's central role in driving the cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class monoclonal antibody designed to neutralize CCL24, thereby interfering with the primary pathways that promote these conditions. Nebokitug has demonstrated disease-modifying potential in multiple clinical trials and has received Orphan Drug and Fast Track designations from the U.S. FDA for the treatment of primary sclerosing cholangitis (PSC). Following positive Phase 2 results, the company is preparing for a potential Phase 3 trial for nebokitug in PSC.

Recent filings

Filing Released Lang Actions
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by BioCancell Ltd., a foreign private issuer, under the SEC Securities Exchange Act of 1934. It contains announcements about a potential merger feasibility study, a capital raising prospectus involving issuance of shares, and updates on clinical trial progress and drug development plans. The document includes detailed information about the capital raising offering, including share units, pricing, and use of proceeds, which are typical of capital/financing updates. It does not contain full financial statements or comprehensive financial performance data that would classify it as an Annual Report (10-K) or Interim Report (IR). It is not a simple announcement of a report publication or a certification. The primary focus is on financing activities and merger feasibility, fitting best under Capital/Financing Update (CAP). The document length (9737 characters) supports it being a substantive filing rather than a brief announcement.
2012-11-05 English
6-K
M&A Activity Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, BioCancell Ltd., with the SEC. It reports on preliminary discussions about a potential merger with another company, Proteologics Ltd., and details about a shareholders meeting approving a capital raise via issuance of shares. It also includes information about the exercise period of Series 1 Warrants. The document is an announcement of ongoing merger evaluation and shareholder approval for a capital raise, not a full merger agreement or financial report. It does not contain comprehensive financial statements or detailed merger documentation but rather an update on merger feasibility and shareholder approvals. Therefore, it fits best under the category of M&A Activity (TAR) as it relates to merger proposals and related announcements.
2012-10-22 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by BioCancell Ltd., which is a report of a foreign private issuer pursuant to SEC rules under the Securities Exchange Act of 1934. It contains condensed consolidated interim financial statements as of June 30, 2012, including statements of financial position, operations, changes in equity, and cash flows, along with notes. The document references the second quarter of 2012 and includes unaudited interim financial data and pro forma financial statements related to a merger. The presence of detailed interim financial statements and notes indicates this is a comprehensive interim/quarterly report rather than a brief announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2012-10-02 English
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, BioCancell Ltd., with the SEC. It contains announcements about a call for a general meeting to approve a prospectus for raising capital and details about a loan agreement with a controlling shareholder. The content focuses on corporate actions and financing updates rather than full financial statements or detailed financial performance. The document length is 9219 characters, which is substantial but the content is primarily about financing and shareholder meeting announcements related to capital raising and loan agreements. There is no comprehensive financial report or earnings data presented. Therefore, the document best fits the category of Capital/Financing Update (CAP).
2012-10-01 English
6-K
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, BioCancell Ltd., reporting on changes in the company's board of directors. It details the appointment of two external directors and the resignation of one director, including voting results from a shareholders meeting. There is no financial data or report content, only management and board changes. This fits the category of Board/Management Information (MANG). The document length is 5775 characters, sufficient to contain detailed information about board changes. Therefore, the classification is MANG with high confidence.
2012-09-04 English
6-K
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed by BioCancell Ltd., a foreign private issuer, under the SEC Securities Exchange Act of 1934. It announces a general meeting of shareholders to approve the appointment of external directors, including detailed biographies and legal context. The content focuses on board/management changes and governance compliance, specifically the appointment of external directors as required by Israeli law. There are no financial statements or earnings data, nor is this a report publication announcement or certification. The primary subject is the announcement of changes in the company's board of directors. Therefore, the document fits best under Board/Management Information (MANG). The document length (7225 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2012-08-20 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.